A Phase 1 Clinical Study to Assess Safety and Efficacy of Oral Fingolimod (FTY720) in Children With Rett Syndrome.
Phase of Trial: Phase I
Latest Information Update: 22 Jun 2018
Price : $35 *
At a glance
- Drugs Fingolimod (Primary)
- Indications Rett syndrome
- Focus Therapeutic Use
- Acronyms FINGORETT
- 31 Aug 2018 Biomarkers information updated
- 14 Jun 2018 Status changed from active, no longer recruiting to completed.
- 06 Apr 2018 Planned primary completion date changed from 1 Mar 2018 to 1 May 2018.